- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07648953
Microvideos for Improving HPV Vaccination Among Childhood Cancer Survivors
This exploratory mixed-methods study aims to examine receipt of treatment and decision-making among rural cancer patients in Utah. Guided by Conceptual Model of Healthcare Access, the study will integrate, survey and cancer registry data with patient interviews to better understand how travel burden, socioeconomic conditions, health literacy, and other contextual factors shape treatment location and access to care . While the setting of this research is specific to Utah, a state with vast rural regions and only one National Cancer Institute (NCI)-designated cancer center, the findings may inform policy and practice improvements in other states with similar geographic and healthcare infrastructure. Thus, the study has potential relevance for advancing rural cancer equity nationwide.
Understanding how rural cancer patients make treatment decisions is essential to addressing persistent disparities in cancer care access and outcomes. While geographic barriers and structural inequities are well-documented, less is known about the individual and contextual factors that shape patients' choices about where and how to receive treatment. This mixed-methods study will examine receipt of treatment, decision-making, and patient experience among rural cancer patients in Utah, with attention to travel burden, referral pathways, health literacy, and perceived barriers to care.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Echo Warner, MPH, PhD, SB
- Telefoonnummer: 801-244-7040
- E-mail: echo.warner@hci.utah.edu
Studie Locaties
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84112
- Werving
- University of Utah
-
Contact:
- Echo Warner, MPH, PhD, SB
- Telefoonnummer: 801-244-7040
- E-mail: echo.warner@hci.utah.edu
-
Hoofdonderzoeker:
- Echo Warner, MPH, PhD, SB
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Eligible participants include cancer survivors who are currently ages 18-26 years and who were diagnosed with childhood cancer (ages 0-26 at diagnosis) in the past ten years.
- Currently use Facebook or willing to create a Facebook account to use for the duration of the study.
- At the time of enrollment, have not completed all recommended doses of the HPV vaccine.
Exclusion Criteria:
- Unable to speak and understand English.
- Participants who take part in the Aim 1 focus groups will be ineligible for the Aim 2 social media group.
- Participants who are fully vaccinated for HPV will be ineligible as the goal of Aim 2 is to evaluate the feasibility of the social media campaign for improving vaccine intention among HPV unvaccinated individuals.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: HPV Vaccination Education
Microvideos are designed to be <2 minutes long and to address key information on a topic in an engaging and concise manner.
HPV vaccine education will be provided to unvaccinated emerging adult survivors of childhood cancer through a pilot quasi-experimental social media intervention.
|
To educate survivors of childhood cancers about a key cancer prevention strategy, HPV vaccination.
The core microvideos will focus on the 5 Ws of HPV vaccination: Who should get vaccinated, What HPV vaccination protects against, When to get vaccinated, Where to access the vaccine, Why it matters-designed particularly for cancer survivors.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Feasibility of Microvideo education
Tijdsspanne: up to 4 weeks
|
Feasibility will be defined as ≥80% of participants completing the intervention and study surveys.
|
up to 4 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Acceptability of Microvideo Education
Tijdsspanne: up to 4 weeks
|
Acceptability will be summarized using means, standard deviations, and proportions of participants indicating strong agreement (scores ≥4 out of 5) with positive statements about the microvideos and platform. Scores range from 0-5, with higher scores indicating more positivity about the microvideos and platform, and lower scores indicating less positivity about the microvideos and platform. |
up to 4 weeks
|
|
Satisfaction Acceptability of Microvideo Education
Tijdsspanne: up to 4 weeks
|
Satisfaction will be summarized using means, standard deviations, and proportions of participants indicating strong agreement (scores ≥4 out of 5) with positive statements about the microvideos and platform. Scores range from 0-5, with higher scores indicating more positivity about the microvideos and platform, and lower scores indicating less positivity about the microvideos and platform. |
up to 4 weeks
|
|
HPV Vaccine Intention
Tijdsspanne: up to 4 weeks
|
To assess HPV vaccine intention among unvaccinated emerging adult survivors of childhood cancer through a pilot quasi-experimental social media intervention. This outcome measure will report the count of participants who intended to receive the HPV Vaccine after the microvideo education. |
up to 4 weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Echo Warner, MPH, PhD, SB, Huntsman Cancer Institute
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- 198894
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .